BRPI0516468A - composição farmacêutica para o tratamento de xeroftalmia e xerostomia - Google Patents

composição farmacêutica para o tratamento de xeroftalmia e xerostomia

Info

Publication number
BRPI0516468A
BRPI0516468A BRPI0516468-0A BRPI0516468A BRPI0516468A BR PI0516468 A BRPI0516468 A BR PI0516468A BR PI0516468 A BRPI0516468 A BR PI0516468A BR PI0516468 A BRPI0516468 A BR PI0516468A
Authority
BR
Brazil
Prior art keywords
xerophthalmia
xerostomia
treatment
pharmaceutical composition
increased
Prior art date
Application number
BRPI0516468-0A
Other languages
English (en)
Inventor
Yohei Okada
Ken Ikeda
Fumikazu Wanibuchi
Keiichi Yoshihara
Hiromu Kondo
Hiroyuki Kojima
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BRPI0516468A publication Critical patent/BRPI0516468A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSIçãO FARMACêUTICA PARA O TRATAMENTO DE XEROFTALMIA E XEROSTOMIA. A presente invenção tem como problemas: fornecer um agente terapêutico para xeroftalmia e xerostomia o qual é livre de efeitos indesejáveis. Meio para solucionar os problemas: com a administração de um composto A constatou-se o aumento da secreção da saliva e lágrima sem perspiração e através da liberação controlada, constatou-se ainda o aumento da multiplicação das células da glândula lacrimal e da glândula salivar.
BRPI0516468-0A 2004-10-05 2005-10-04 composição farmacêutica para o tratamento de xeroftalmia e xerostomia BRPI0516468A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004292611 2004-10-05
PCT/JP2005/018310 WO2006038596A1 (ja) 2004-10-05 2005-10-04 涙液及び唾液乾燥症治療用医薬組成物

Publications (1)

Publication Number Publication Date
BRPI0516468A true BRPI0516468A (pt) 2008-09-09

Family

ID=36142669

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516468-0A BRPI0516468A (pt) 2004-10-05 2005-10-04 composição farmacêutica para o tratamento de xeroftalmia e xerostomia

Country Status (15)

Country Link
US (2) US20070105934A1 (pt)
EP (1) EP1712230A1 (pt)
JP (1) JPWO2006038596A1 (pt)
KR (1) KR20070061578A (pt)
CN (1) CN101031297A (pt)
AU (1) AU2005290532A1 (pt)
BR (1) BRPI0516468A (pt)
CA (1) CA2582615A1 (pt)
IL (1) IL182124A0 (pt)
MX (1) MX2007003994A (pt)
NO (1) NO20072328L (pt)
RU (1) RU2007116944A (pt)
TW (1) TW200616628A (pt)
WO (1) WO2006038596A1 (pt)
ZA (1) ZA200702784B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090082381A1 (en) * 2005-07-26 2009-03-26 Akiharu Isowaki Percutaneously Absorbable Ophthalmic Preparation
US10338203B2 (en) 2011-09-09 2019-07-02 Siemens Medical Solutions Usa, Inc. Classification preprocessing in medical ultrasound shear wave imaging
JP6526475B2 (ja) * 2015-04-30 2019-06-05 サンスター株式会社 経皮唾液腺投与用の唾液分泌促進剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2683783B2 (ja) * 1992-07-10 1997-12-03 雪印乳業株式会社 シェーグレン症候群治療剤
ATE219933T1 (de) * 1992-09-18 2002-07-15 Yamanouchi Pharma Co Ltd Hydrogelzubereitung mit verzögerter freisetzung
JPH07126163A (ja) * 1993-10-08 1995-05-16 Theratech Inc 制御放出性ピロカルピン送達システム
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US20020142033A1 (en) * 1998-05-05 2002-10-03 Gupta Suneel K. Method for treating incontinence
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
JP2003063964A (ja) * 2001-08-28 2003-03-05 Senju Pharmaceut Co Ltd ドライアイまたはドライアイを伴なう疾病の予防治療剤

Also Published As

Publication number Publication date
TW200616628A (en) 2006-06-01
CN101031297A (zh) 2007-09-05
US20070105934A1 (en) 2007-05-10
US20080131511A1 (en) 2008-06-05
EP1712230A1 (en) 2006-10-18
AU2005290532A1 (en) 2006-04-13
NO20072328L (no) 2007-06-29
MX2007003994A (es) 2007-06-15
KR20070061578A (ko) 2007-06-13
CA2582615A1 (en) 2006-04-13
ZA200702784B (en) 2008-09-25
WO2006038596A1 (ja) 2006-04-13
RU2007116944A (ru) 2008-11-20
IL182124A0 (en) 2007-07-24
JPWO2006038596A1 (ja) 2008-05-15

Similar Documents

Publication Publication Date Title
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
CL2011000488A1 (es) Compuestos derivados de pirazolo-pirimidinas sustituidas; composicion y combinacion farmaceutica que los comprenden; y su uso como inhibidores de pde9 para el tratamiento, alivio y/o prevencion de deterioros cognitivos relacionados con la percepcion, alzheimer,trastornos del sueño, trastorno bipolar, diabetes mellitus.
PE20142440A1 (es) Composiciones farmaceuticas orales de liberacion inmediata con recubrimiento no enterico que comprende 5-azacitidina
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
DOP2006000057A (es) Composición farmaceútica para el tratamiento del cáncer
CR8428A (es) Agente endoparasiticidas para la administracion topica
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
CR11723A (es) Agente para tratar enfermedad
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
BRPI0912411A8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro.
ATE534378T1 (de) Titrierung von tapentadol
GT200500137A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
UY33700A (es) ?combinaciones farmacéuticas para el tratamiento de trastornos metabólicos?.
UY31079A1 (es) Derivados de fenilaminobenceno sustituidos de utilidad para el tratamiento de trastornos y enfermedades hiperproliferativos asociados con actividad quinasa extracelular mediada por mitógenos
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
CL2010001123A1 (es) Uso de piridin-3-ilmetil docosahexanoato para preparar un medicamento util para la prevencion y/o el tratamiento de enfermedades cardiovasculares (divisional solicitud 1848-07).
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
CL2013000736A1 (es) Uso de prodrogas ester de [3-(1-(1h-imidazol-4-il)etil)-2-metil-fenil]metanol para preparar un medicamento util en el tratamiento de enfermedades de la retina tales como degeneracion macular humeda y seca, y retinopatia diabetica; y uso de la composicion que comprende a dichos compuestos.
PL1680128T3 (pl) Heksafosforan mio-inozytolu do stosowania miejscowego
EA201401231A1 (ru) Фармацевтические комбинации, предназначенные для лечения метаболических нарушений
BR112018014661A2 (pt) composição e composição para uso
BRPI0516468A (pt) composição farmacêutica para o tratamento de xeroftalmia e xerostomia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.